Scarica l'app Stockscreener
0.281
0.57%
-0.0016
Dopo l'orario di chiusura:
.28
-0.001
-0.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.2826
Aprire:
$0.2837
Volume 24 ore:
1.22M
Relative Volume:
0.09
Capitalizzazione di mercato:
$12.47M
Reddito:
$1.04M
Utile/perdita netta:
$-67.50M
Rapporto P/E:
-0.1462
EPS:
-1.9222
Flusso di cassa netto:
$-60.67M
1 W Prestazione:
+2.93%
1M Prestazione:
+14.23%
6M Prestazione:
-52.10%
1 anno Prestazione:
-92.19%
Intervallo 1D:
$0.2778
$0.2999
Intervallo di 1 settimana:
$0.268
$0.319
Portata 52W:
$0.198
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Nome
Vistagen Therapeutics Inc
Settore
Industria
Telefono
650-577-3600
Indirizzo
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.281 | 12.11M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Downgrade | Maxim Group | Buy → Hold |
| 2025-12-17 | Downgrade | Stifel | Buy → Hold |
| 2025-12-17 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-07 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-07-22 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Iniziato | Robert W. Baird | Outperform |
| 2021-02-18 | Iniziato | Jefferies | Buy |
| 2021-01-04 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Iniziato | Maxim Group | Buy |
| 2018-02-08 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie
Vistagen Therapeutics, Inc. (VTGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
VTGN News | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Form 8K VistaGen Therapeutics Inc For: 25 September By Investing.com - Investing.com Nigeria
VistaGen Updates Strategy for Pherine-Based CNS Therapies - TipRanks
Three anxiety drug trials missed their goals. Vistagen (VTGN) proposes another after one met its goal. - Stock Titan
Vistagen Therapeutics, Inc. (VTGN) stock price, news, quote and history - Yahoo Finance Singapore
Vistagen Therapeutics Shares Positive Fasedienol Nasal Spray Data at Psych Congress 2026 - kalkinemedia.com
Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder - Yahoo Finance
Vistagen presents exploratory data on social anxiety treatment - Investing.com
Vistagen (VTGN) Reports Positive Phase 3 Social Anxiety Data Ami - GuruFocus
Vistagen presents exploratory data on social anxiety treatment By Investing.com - Investing.com Canada
A Phase 3 trial missed its main goal overall, despite a possible nasal-spray benefit in very severe cases. - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Vistagen Therapeutics, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (VTGN) - Traders Union
Vistagen Therapeutics Surges on Positive Extension Data for Fasedienol - Quiver Quantitative
Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
$VistaGen Therapeutics (VTGN.US)$ dont panic analyst said is 1 - Moomoo
Top Premarket Gainers - Yahoo Finance
Vistagen (VTGN) Reports Positive Phase 3 OLE Data Amid Challengi - GuruFocus
VistaGen Reports Positive Long-Term Fasedienol Anxiety Data - TipRanks
Vistagen reports positive open-label extension safety and exploratory efficacy for fasedienol in social anxiety - TradingView
Year‑long nasal spray use at Vistagen (NASDAQ: VTGN) lowers social anxiety scores as FDA talks approach - Stock Titan
Good Luck~ $VistaGen Therapeutics (VTGN.US)$ - Moomoo
Vistagen Announces Preliminary Positive Data from - GlobeNewswire
Preliminary data: social anxiety scores improved 31 points in four months with Vistagen’s nasal spray - Stock Titan
This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell - Stocktwits
Vistagen Therapeutics shareholders elect board members and approve key proposals By Investing.com - Investing.com Australia
Form 8K VistaGen Therapeutics Inc For: 11 September By Investing.com - Investing.com Nigeria
VistaGen Stockholders Reaffirm Board, Governance and Oversight - TipRanks
Vistagen Therapeutics shareholders elect board members and approve key proposals - Investing.com India
Stockholders at Vistagen (NASDAQ: VTGN) back board slate, executive pay and KPMG - Stock Titan
Vistagen to Present at Psych Congress 2026 - GlobeNewswire
VistaGen Therapeutics Inc. (VTGN) Peer Comparison – Compare with Others - Value Research
VistaGen Therapeutics Inc. (VTGN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Vistagen Therapeutics (VTGN) Slides 4.31% to $0.24, Testing Key Support at $0.23Box Spread - vinanet.vn
Vistagen Therapeutics Lawsuit: Company Seeks Dismissal of Investor Securities Claims - TipRanks
VistaGen Therapeutics Inc. (VTGN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Vistagen Therapeutics Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock Slips 1.56%CEO Earnings Statement - dars.gov.et
Vistagen (VTGN) Trading: Gains 1.20% to Reach $0.24 on the Day; the Current Price Sits Inside the Supplied Technical Range in the Available RecordLeveraged ETF Flow - vinanet.vn
VistaGen Therapeutics earnings missed by $0.05, revenue topped estimates - Investing.com Canada
VistaGen Therapeutics (VTGN) Institutional Ownership 2026 - MarketBeat
Vistagen Therapeutics: Runway To Fund Operations Into 2027 >VTGN - Moomoo
William Blair Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating - Moomoo
Vistagen Therapeutics Releases Q1 2027 Financial Results - AlphaStreet
Vistagen Therapeutics (VTGN): OrbiMed reports 0.0% beneficial ownership in latest 13G/A - Stock Titan
Vistagen Therapeutics (VTGN) investor Chen Yu reports 6.7% warrant-based stake - Stock Titan
Vistagen Therapeutics (VTGN) flags going concern risk amid Q1 loss and Nasdaq pressure - Stock Titan
Vistagen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
Vistagen Therapeutics (VTGN) investor reports 4.24M-share, 9.9% stake - Stock Titan
Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com - Investing.com India
Vistagen Therapeutics Inc Azioni (VTGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):